Matches in Nanopublications for { ?s ?p "[The median 6-mercaptopurine dose administered during the maintenance therapy was 31% lower among patients with heterozygous TPMT alleles versus the rest (32.1mg/m(2)/day and 46.2mg/m(2)/day, p=0.005), though the myelosuppression and toxicities were similar in both the groups.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 2 of
2
with 100 items per page.
- NP756652.RAZ_vZo63inHnVzaYjbYiDM04yckc3k0rq7vmYbfywJVg130_assertion description "[The median 6-mercaptopurine dose administered during the maintenance therapy was 31% lower among patients with heterozygous TPMT alleles versus the rest (32.1mg/m(2)/day and 46.2mg/m(2)/day, p=0.005), though the myelosuppression and toxicities were similar in both the groups.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP756652.RAZ_vZo63inHnVzaYjbYiDM04yckc3k0rq7vmYbfywJVg130_provenance.
- NP793574.RA3mqmXVFNjMjWADCRfNe_IYiOey2ADikmbeuUVKKXLyw130_assertion description "[The median 6-mercaptopurine dose administered during the maintenance therapy was 31% lower among patients with heterozygous TPMT alleles versus the rest (32.1mg/m(2)/day and 46.2mg/m(2)/day, p=0.005), though the myelosuppression and toxicities were similar in both the groups.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP793574.RA3mqmXVFNjMjWADCRfNe_IYiOey2ADikmbeuUVKKXLyw130_provenance.